Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Acta Biomater. 2015 Sep 15;28:23–32. doi: 10.1016/j.actbio.2015.09.018

Table 1. Design of SCI combination therapy study.

All groups had fibrin as the scaffold and included some combination of heparin, ATIII peptide, GFs (NT-3 & PDGF), NEP1–40 PLGA microspheres, ChABC lipid microtubes, and pMNs.

Combination Scaffolds Heparin ATIII peptide NT-3/PDGF NEP1–40 PLGA
microspheres
ChABC lipid
microtubes
Selected
pMNs
GFs (n=5) X X X
pMNs+GFs (n=5) X X X X
AIMS (n=6) X X
pMNs+AIMS (n=7) X X X
GFs+AIMS+pMNs (n=6) X X X X X X